



31 March 2025

Dr David Rosengren
Director-General
Queensland Health

By email: [REDACTED]

Subject: Restriction of medicinal cannabis prescribers to fellows

Dear David


As you know, our organisations have been strongly advocating for increased regulation of medicinal cannabis. Doctors and pharmacists are seeing too many patients harmed by highly concentrated products and inappropriate prescribing, including ED presentations for psychosis.

We have held several meetings with Queensland Health and the Therapeutic Goods Administration to seek sensible solutions. We also wrote to Ministers Nicholls and Butler urging them to act, as have our medical and pharmacy colleagues in other jurisdictions. These efforts have confirmed that current medicinal cannabis business models are exploiting vulnerable health practitioners, particularly early-career doctors and pharmacists with less financial and employment security.

To prevent continued exploitation and harms to patients, our organisations propose medicinal cannabis prescribers be limited to more senior and experienced practitioners who have completed specialist training through a medical college. Queensland Health has advised that this is readily achievable via amendment of the *Medicines and Poisons (Medicines) Regulation 2021* (Qld), similar to existing restrictions for high-risk medicines such as isotretinoin.


We think this is a sensible and efficient approach to improving medicinal cannabis regulation and seek a meeting with you and appropriate Queensland Health representatives to discuss further.

Yours sincerely



Dr Nick Yim
President
AMA Queensland

Prof Brett Emmerson AM
Chair, Queensland Branch
The Royal Australian and New
Zealand College of
Psychiatrists



Chris Owen
President,
The Pharmacy Guild of
Australia, Queensland

Dr Cath Hester FRACGP
Chair, RACGP Queensland